The role of HIF1α in renal cell carcinoma tumorigenesis.

TitleThe role of HIF1α in renal cell carcinoma tumorigenesis.
Publication TypeJournal Article
Year of Publication2014
AuthorsGudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM
JournalJ Mol Med (Berl)
Volume92
Issue8
Pagination825-36
Date Published2014 Aug
ISSN1432-1440
KeywordsAnimals, Carcinoma, Renal Cell, Cell Transformation, Neoplastic, Disease Models, Animal, Disease Progression, Gene Deletion, Gene Expression, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Kidney Neoplasms, Mice, Molecular Targeted Therapy, Mutation, Neoplastic Stem Cells, Stem Cells, von Hippel-Lindau Disease
Abstract

UNLABELLED: The transcription factor HIF1α is implicated in the development of clear cell renal cell carcinoma (ccRCC). Although HIF1α was initially believed to be essential for ccRCC development, recent studies hypothesize an oncogenic role for HIF2α in ccRCC, but a tumor suppressor role for HIF1α, leading to uncertainty as to the precise roles of the different HIF transcription factors in this disease. Using evidence available from studies with human ccRCC cell lines, mouse xenografts, murine models of ccRCC, and human ccRCC specimens, we evaluate the roles of HIF1α and HIF2α in the pathogenesis of ccRCC. We present a convergence of clinical and mechanistic data supporting an important role for HIF1α in promoting tumorigenesis in a clinically important and large subset of ccRCC. This indicates that current understanding of the exact roles of HIF1α and HIF2α is incomplete and that further research is required to determine the diverse roles of HIF1α and HIF2α in ccRCC.

KEY MESSAGES: The TRACK mouse ccRCC model with constitutively active HIF1α but not HIF2α expressed in proximal tubules develops RCC. HIF1α protein is expressed in the majority of human ccRCC specimens. Elevated HIF1α in ccRCC correlates with a worse prognosis. Many publications do not support a tumor suppressor role for HIF1α in ccRCC. HIF1α, but not HIF2α, is expressed in some types of cancer stem cells.

DOI10.1007/s00109-014-1180-z
Alternate JournalJ. Mol. Med.
PubMed ID24916472
PubMed Central IDPMC4119538
Grant ListT32 CA062948 / CA / NCI NIH HHS / United States
T32-CA062948 / CA / NCI NIH HHS / United States